From: Therapeutic strategies in RET gene rearranged non-small cell lung cancer
Prior platinum doublet (n = 105) | |
ORR (%) | 68 (95% CI 58–76) |
Medium DOR (months) | 20.3 (95% CI 13.8–24.0) |
Medium PFS (months) | 18.4 (95% CI 12.9–24.9) |
Treatment naïve (n = 34) | |
ORR (%) | 85 (95% CI 69–95) |
Medium DOR (months) | NR |
PFS (months) | NR |
Patients with measurable CNS metastasis (n = 11) | |
ORR (%) | 91% (95% CI 59–100) |